Drugs / Interferon-gamma (IFN-γ)
Interferon-gamma (IFN-γ)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03112590 | Jun 2017 → Mar 2021 | HER2 positive breast carcinoma, female breast carcinoma, male breast carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Interferon-gamma (IFN-γ) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03112590 ↗ |
| Modality | Protein / enzyme biologic | “Interferon-gamma is a biologically manufactured protein” NCT03112590 ↗ |
| Route | Subcutaneous | “Phase 2: IFN-γ at Recommended Phase II Dose (RP2D) subcutaneously (SQ) x 3 days/week, for 12 weeks.” NCT03112590 ↗ |